Calcium antagonists in the treatment of coronary artery disease.

[1]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.

[2]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physi , 2012, Journal of the American College of Cardiology.

[3]  T. Lauer,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[4]  Edgardo Abalos,et al.  How to manage hypertension in pregnancy effectively. , 2011, British journal of clinical pharmacology.

[5]  N. Sato,et al.  Secondary preventive effects of a calcium antagonist for ischemic heart attack: randomized parallel comparison with β-blockers. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[6]  T. Lüscher,et al.  A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study , 2009, European heart journal.

[7]  S. Bangalore,et al.  Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. , 2009, The American journal of medicine.

[8]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[9]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[10]  G. Filippatos,et al.  2007 Guidelines for the management of arterial hypertension , 2007 .

[11]  R. Collins,et al.  Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. , 2006, European heart journal.

[12]  E. Mohler,et al.  A Randomized, Double‐Blind Trial Comparing the Effects of Amlodipine Besylate/Benazepril HCl vs Amlodipine on Endothelial Function and Blood Pressure , 2006, Journal of clinical hypertension.

[13]  G. Bakris,et al.  Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). , 2006, The American journal of cardiology.

[14]  G. Mancia,et al.  Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. , 2006, European heart journal.

[15]  Alice Stanton,et al.  Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.

[16]  J. Camm,et al.  [Guidelines on the management of stable angina pectoris: executive summary]. , 2006, Giornale italiano di cardiologia.

[17]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[18]  C. Held,et al.  Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS) , 2005, Heart.

[19]  P. Libby,et al.  Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled Trial , 2004 .

[20]  P. Poole‐Wilson,et al.  Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial , 2004, The Lancet.

[21]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[22]  S. Hosoda,et al.  Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[23]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[24]  Peter Sleight,et al.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. , 2003, JAMA.

[25]  R. Schmieder,et al.  Effect of AT1 receptor blockade on endothelial function in essential hypertension. , 2003, American journal of hypertension.

[26]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[27]  Encore Investigators.  Effect of Nifedipine and Cerivastatin on Coronary Endothelial Function in Patients With Coronary Artery Disease: The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function) , 2003, Circulation.

[28]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[29]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[30]  H. Keen,et al.  Mortality and causes of death in the WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.

[31]  H. Drexler,et al.  Comparative Effect of ACE Inhibition and Angiotensin II Type 1 Receptor Antagonism on Bioavailability of Nitric Oxide in Patients With Coronary Artery Disease: Role of Superoxide Dismutase , 2001, Circulation.

[32]  T. Malinski,et al.  Synergistic Antihypertensive Effects of Nifedipine on Endothelium: Concurrent Release of NO and Scavenging of Superoxide , 2001, Hypertension.

[33]  Michael E. Miller,et al.  Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.

[34]  M. Laakso,et al.  Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. , 2000, Diabetes care.

[35]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[36]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[37]  M. Laakso,et al.  Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes , 2000, Diabetologia.

[38]  K. McDonald,et al.  Meta-analysis of Trials Comparing β-Blockers, Calcium Antagonists, and Nitrates for Stable Angina , 1999 .

[39]  T. Hintze,et al.  Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. , 1998, Circulation.

[40]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[41]  J. Kostis,et al.  Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. , 1997, American heart journal.

[42]  M. Pahor,et al.  A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS) , 1996, The American journal of cardiology.

[43]  C. Held,et al.  Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) , 1996, European heart journal.

[44]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[45]  B. Kasiske,et al.  Effects of Antihypertensive Therapy on Serum Lipids , 1995, Annals of Internal Medicine.

[46]  F. Messerli,et al.  Are all calcium antagonists equally effective for reducing reinfarction rate? , 1993, The American journal of cardiology.

[47]  Carr Aa,et al.  ANTIHYPERTENSIVE DRUG THERAPY AND INSULIN RESISTANCE , 1992 .

[48]  A. Fleckenstein.  History of Calcium Antagonists , 1983, Circulation research.

[49]  K. Fox,et al.  Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. , 1996, European heart journal.

[50]  S. Nattel,et al.  Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. , 1991, Circulation.

[51]  Nie Fe.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II) , 1990 .

[52]  A. Fleckenstein.  [THE IMPORTANCE OF ENERGY-RICH PHOSPHATE FOR CONTRACTILITY AND TONUS OF THE MYOCARDIUM]. , 1964, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin.

[53]  R. Preston Mason,et al.  Antihypertensive Agents: Mechanisms of Drug Action (hm Siragy and B Waeber, Section Editors) Pleiotropic Effects of Calcium Channel Blockers , 2022 .